Clinical manifestations, serological profile and treatments history of the patients
| Disease duration (years, median, IQR) | 13; 7.5–17 |
| N (%) | |
| Cumulative organ involvement | |
| Renal | 27 (93.1) |
| Joint | 27 (93.1) |
| Skin | 19 (65.6) |
| Haematological | 18 (62) |
| Serositis | 12 (41.4) |
| Neuropsychiatric | 2 (6.9) |
| Cumulative serology | |
| ANA | 29 (100) |
| Anti-dsDNA | 25 (86.2) |
| Anti-RNP | 15 (51.7) |
| Anti-Sm | 14 (48.3) |
| aPL | 12 (41.4) |
| Anti-SSA | 11 (37.9) |
| Anti-SSB | 3 (10.3) |
| Previous IS therapies | |
| Azathioprine | 19 (65.5) |
| Mycophenolate mofetil | 5 (17.2) |
| Cyclophosphamide | 21 (72.4) |
| Methotrexate | 5 (17.2) |
| Rituximab | 12 (41.4) |
| Belimumab | 4 (13.8) |
ANA, antinuclear antibodies; Anti-RNP, anti-ribonucleoprotein antibodies; Anti-SSA, anti Ro/SSA antibodies; Anti-SSB, anti-La/SSB antibodies; Anti-dsDNA, anti-double stranded DNA antibodies; aPL, antiphospholipid antibodies; IS, immunosuppressive.